Other research has since tied GLP-1 receptor agonists to other eye conditions, including age-related macular degeneration and ...

Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

Fish treated with SGLT2 inhibitors maintained healthier kidneys as they aged. Their kidneys preserved denser networks of capillaries, retained a stronger filtration barrier, and showed more stable ...

SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the clinical impact.

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Starting SGLT2 inhibitors led to a lower risk of eGFR ...

Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis. The FDA previously issued guidance on withholding SGLT2 inhibitors ...

SGLT2 inhibitors are one of many medicines you may take to treat type 2 diabetes. They also can protect your kidneys and make heart failure less likely. (Photo Credit: Moment RF/Getty Images) SGLT2 ...

Explore novel therapies for IgA nephropathy that target inflammation and antibody production. Learn how these advancements ...

Kidney aging rarely draws attention until something goes wrong. Over time, these organs quietly lose strength, filter less efficiently, and struggle to keep the body balanced. A new study now brings ...

When canagliflozin (Invokana) was approved in 2013, the SGLT2 inhibitor was touted as a first in a new medication class that was, at the time, the only oral, once-daily medication to reduce blood ...

Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...